“Get Informed, Get Screened, Get Vaccinated” – WHO
Introduction:
Cervical cancer is the 4th most common cancer among women and 7th most commonly occurring cancer overall. When a malignant growth or tumor occurs in the cells lining the walls of the cervix, it is called cervical cancer. The cervix is the narrow, lower part of the uterus…
Shots:
Dr. Richard talked about the results from the NefIgArd P-III trial evaluating Tarpeyo (Nefecon) for the treatment of IgA Nephropathy
He also highlighted the safety and efficacy results from the NefIgArd study. He also spoke more about Trapeyo and the roadmap for its global approval and commercialization
The interview shows up how Calliditas is…
Shots:
Roche was the top dealmaker in 2022 with a completion of 31 deals with multiple pharma, biotech companies, and universities for a total deal value of $13.55B
The highest deal was secured by Roche under its development and commercialization collaboration with Poseida for the R&D of multiple existing and novel cell therapies for the…
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients
During the month of December, Alvotech and STADA launched Hukyndra (biosimilar, adalimumab)…
Shots:
Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DME
Jeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DME
The interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…
The year 2022 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements, clinical trial results and gaining approvals. Our team has compiled a list of 30 most read life sciences news on PharmaShots in 2022
1. AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to…
Need Coverage of 41st Annual J.P. Morgan Healthcare Conference 2023?
Shots:
The 41st Annual J.P. Morgan Healthcare Conference (JPM 2023) will take place from January 9th to 12th, 2023, in San Francisco, US. It will gather thousands of global investors, emerging companies, innovative technology creators, and members of the investment community
With hundreds of presentations lined up…
Shots:
The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6B
In the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…
Shots:
The EMA approved 4 New Chemical Entity (NCE) and 4 Biologic Drugs in November 2022, leading to treatments for patients and advances in the healthcare industry
In November 2022, the major highlights drugs were Skyrizi's approval for active crohn's disease, Beyfortus for RSV lower respiratory tract disease
PharmaShots has compiled a list of a…
Shots:
Brian talked about the $17 million in Series A funding led by Blue Ledge Capital including other ventures
Brian also spoke about multiple products being developed in Qnovia’s pipeline. The funding will advance its NRT drug candidate through an IND submission in 2023
The interview gives an understanding of how Qnovia is developing innovative…

